$500 million or RMB It's not clear.
Summarized 2013-2014, 53 domestic medical device mergers and acquisitions.
Acquirer
Bidder
Field
Remarks
Xinhua Medical
Westar Medical
Clinical Testing
December 2013 wholly-owned subsidiary Hua Tuo International Development to acquire 60% of Westar Medical Ltd. for $384.3 million.
Xinhua Medical
Yuanyue System Machine
Pharmaceutical Equipment
June 2013, $353 million to acquire 90% equity interest in Shanghai Yuanyue Pharmaceutical Machinery
Dongfulong
Jianzhong Medical
Sterilization Packaging and its Materials
November 2013, $40 million to participate in the Shanghai Jianzhong Medical Devices Packaging Co., Ltd. and acquire part of the shares, holding no less than 20% of the shares
Dongfulong
Shanghai Paradigm
Biomedical materials
November 2013, invested no more than $35 million, to acquire part of the shares of Shanghai Paradigm Medical Science & Technology and increase the capital, holding no less than 51% of the shares
Kelitai
Esun Technology
Cardiovascular stents
July 2013, 139.7 million to acquire 29.73% of the equity of Esun Technology (Beijing), and plans to gradually acquire the remaining shares in 2014 until it holds a 100% stake
Aidil
Orthopaedic
November 2013, through the issuance of additional shares and cash. In November 2013, the company acquired 80% of the shares of Aidil Medical Devices Sdn Bhd by issuing additional shares and cash at a consideration of RMB528 million
Monfari
OGAWA
Massage Products
November 2013, the company acquired OGAWA, a company listed on the main board of the Bursa Malaysia Securities Berhad, at a price of RMB 270 million
KeXin Bio
ZhongShan Ruifu
Medical Devices Sdn Bhd, an orthopaedic company.
Zhongshan Ruifu
Blood Collection Needle
BaoLite
Dotai Medical
Dialysis Machine
BaoLite
HengXin Bio
Hemodialysis Concentrate, Hemodialysis Dry Powder
June, 2013, the company acquired 100% equity interest of Liaoning Hengxin Bio with the capital raised of RMB 14.56 million and increased capital by RMB 12 million. In June 2013, the company acquired 100% of the equity of Liaoning Hengxin Biotechnology with over-provisioned fund of RMB 14.56 million and increased capital by RMB 12 million, totaling RMB 26.56 million.
Leopold Medical
Xinshuaike
Clopidogrel, etc.
In June 2013, the company acquired 60% equity of Henan Xinshuaike for RMB 390 million.
Renfo Pharmaceutical
Beijing Medical
Diagnostic reagents
Shangrong Medical
Puld Medical
Sanitary materials
Shangrong Medical
Shangrong Medical
Puld Medical
Sanitary materials
August 2013, a total of 90 million yuan. 50 million yuan was used to increase the capital of Polde Medical, acquiring a 30.56% stake in the company; 40 million yuan was used to acquire Polde Holding's 24.44% stake in Polde Medical.
CRC Vandong
Shanghai China Resources Medical Instruments
Imaging
Stryker
Trunson Holdings
Orthopaedics
January 2013, Stryker's acquisition of a 100% stake in TranSwitch for HK$5.9 billion was the largest M&A activity of the year.
Genesis Holdings
Genesis Billion Medical
Surgical Instruments
Hega Corporation
Sichuan SiXun
Healthcare Informatization
May 2013, the subsidiary acquired 9 software copyright assets of Sichuan SiXun, covering Hospital Management Information System (HIS), Clinical Management Information System (CIS) and Regional Medical and Healthcare Service System (GMIS)
Jiasitang
Guangzhou Jijian
Device Distribution
--
Baijin Medical
Medical Devices
Davey Medical
Ningbo Xing Medical
Infusion Pumps
November, 2013, the subsidiary proposed to RMB4.4 million to acquire 100% equity interest in Ningbo Yongxing Medical Instruments and RMB5 million to increase capital. After the completion of the transaction, the registered capital of Yongxing Medical is RMB 8 million, and the company holds 100% equity interest in Yongxing Medical.
CYHEC
Guangzhou Exxon
Diagnostic reagents
In January 2014, CYHEC acquired 40% of Dachan Biologicals for RMB 5.72 million and became the first major shareholder
On August 6, 2014, the company increased its capital to Exxon by RMB 28.53 million in cash in three phases and conditionally, and became the controlling shareholder. holding 51% of Exxon's equity.
Xilong Chemical
New Continental
Tumor diagnostic reagents
January 2014, proposed 92.25 million yuan to be acquired by the 75% stake in Fujian New Continental Biotechnology Co. Approval of more than 40, including 3 tumor markers
Yonghe Sunshine
Diagnostic reagents
September 2014, the company's capital contribution accounted for 95.14% of the Jiaxing Qingshi Xilong Equity Investment Fund intends to increase its capital by 60.465 million yuan to the Yonghe Sunshine (Hunan) Biotechnology Company Limited, and after the increase of the capital, it will hold a 53.18% shareholding in Yonghe Sunshine.
Yabao Pharmaceutical
Taiyige Electronics
Help to listen
In January 2014, wholly-owned subsidiary Beijing Yabao Investment intends to invest 35 million to transfer the natural person Huang Zhaoming held 8.64% of the equity of Taiyige Electronics, 15 million yuan of capital increase of 3.16% of the equity, after the completion of the **** hold 10.52% of the equity.
Sanno Bio
Huaguang Biotech
Diagnostic reagents
February 2014, Sanno Biotech 2.64 hold no more than 20% of the shares of Huaguang Biotech, becoming the largest shareholder.
Fosun Pingyao
CML
Telemedicine
February 2014, Fosun Pharmaceuticals' wholly-owned subsidiary Fosun Industrial (Hong Kong): participated in the privatization of Chindex Mutual and acquired a 30% stake in CML, expanding its healthcare services and medical devices business.
Chanshan Pharmaceutical Machinery
Honghao Gene
Gene Chip
March 13, 2014, the acquisition of part of the equity of Hunan Honghao Gene Biotechnology Company Limited and its capital increase. The investment is proposed to be 38.18 million yuan.
Guanhao Bio
Yudeqing
Research and development of artificial cornea
March 2014, proposed to invest*** RMB40 million to Yudeqing in phases, and Guanhao Bio accounted for 33.3% of the registered capital after the investment was completed.
Hainan Haiyao
American Bionic Eye Company
Biomaterials
March 2014, the controlling subsidiary of Shanghai Lixinte Medical Science and Technology Co. Ltd. participated in the American Bionic Eye Company with not more than 3 million U.S. dollars and acquired 16% of its equity.
Yuyue Science and Technology
Huarun Wandong
Imaging equipment, surgical instruments, sanitary materials, etc.
In April 2014, it acquired a 51% stake in Huarun Wandong and a 100% stake in Shanghai Medical Devices Group.
Xinhua Medical
Yinde
Biopharmaceutical equipment
In April 2014, proposed to acquire an 85% stake in Yinde for 370 million yuan
BaoLite
BoaoTiansheng
Hemodialysis
In June 2014, used its own funds of 18 million yuan to make an acquisition of Tianjin Ltd. with its own capital of 18 million yuan, accounting for 70% of the subject company's equity,
Beida Pharmaceuticals
One Medical
Tumor Ablation
June 18, 2014,,,proposed to 1.402 billion yuan to buy 100% equity in Shenzhen One Medical, all paid by issuing shares.
Hanyu Pharmaceuticals
Chengji Bio
Syringe
August 20, 2014, proposed to buy 100% equity of Gansu Chengji Bio-Pharmaceutical Co Ltd by issuing shares and paying cash, 1.3 billion.
Puhua Heshun
Tianxinfu
Durability
August 2014 Puhua Heshun Group (01358), CNY800 million to acquire all the shares of Beijing Tianxinfu Medical Co. Regenerative medical biomaterial artificial dura mater for neurosurgery, a pioneer and leader in the industry
Leopold Medical
Yalian Baidu
Diagnostic reagents
August 2014, proposed to use self-financing funds of RMB 153,818,200 yuan to invest in a 42.11% equity interest in Beijing Yalian Baidu Science and Trade Co, Ltd. to become the second largest shareholder.
125 million investment in 71.39% of the equity of Beijing Haihetian Technology Development Co.
36.42 million investment in Beijing Jinwei Jie Technology Development (family medical health comprehensive service platform), 51% stake.
14 million and by the proposed company's core management and technical team *** with the investment in the formation of Ningbo Meilian Tong Investment Management Center, 70% stake;
Liang Manchu
Jingbai Medical
Monitor
August 2014, Tianmu Pharmaceuticals to 7.29 million yuan price of the holding of the Shenzhen Jingbai Medical Equipment Co. 60% stake to Liang Manchu, a shareholder of the company.
Beilu Pharmaceuticals
Shihe Genetics
Gene Sequencing
In August 2014, it proposed to increase its capital to Nanjing Shihe Genetic Biotechnology Co. by 30 million yuan, and after the increase, it would participate in 20% of the equity stake
Chutian Science and Technology
Xinhuanetong
Pharmaceutical water equipment
In August 2014, Tianmu Pharmaceuticals proposed to issue shares at a price of 7.29 million yuan to the shareholder Liang Manchu of Shenzhen Jingbai Medical Equipment Co.
2014 In August 2014, proposed to purchase 100% equity interest in Xinhua Tong by a combination of share issuance and cash payment
Changchun High-Tech
Edvance
Degradable metal coronary stents and orthopedic implants
August 2014, 33,440,700 distributions to increase the capital of Edvance by 44.5%
Shang Rong Medical
Jinzhou Medical Instruments
Orthopedic Bone Joint Implants
September 2014, proposed to use 101.4 million yuan in cash to acquire 66.21% equity interest in Zhangjiagang Jinzhou Medical Instruments Manufacturing Co.
Huaping Stock
Beijing Conrad
Medical Quality Inspection and Digital Information System
September 2014, a 20M capital increase in Beijing Conrad to get 40% equity
Lidman
Desai Diagnostics
Diagnostic reagents
September, 2014, Lidman 180 million with 3 *** same investors to buy Desai Diagnostic Systems (Shanghai) Co. and its part of the equity of Desai products. After the completion of this transaction, Lidman will hold 25% and 31% equity in each of Desai System and Desai Products.
Vivo; Carlyle Fund
Haier Specialty Appliances
Medical Devices
In September 2014, Carlyle Investment Group was awarded a 30% stake in Qingdao Haier Specialty Appliances Co. for 405 million yuan, Vivo Capital will hold 8% in Specialty Appliances, and Haier Venture Capital will hold a 40% stake.
Jiasitang
Xinshunhe
Instrument distribution
September 2014, it is proposed to acquire a portion of the equity of 23 companies, including Sichuan Xinshunhe Trade Co. for 250 million yuan, and after the acquisition is completed, it will account for 51% of the equity, becoming the first major shareholder and de facto controller.
Lanfan Medical
Liming Medical
Hemodialysis
October 2014, wholly-owned subsidiary Lanfan (Shanghai) Asset Management Co., Ltd. jointly with the company's related party, Fuzhou Dongze Medical Devices, to 8.645 million yuan and 4.355 million yuan to acquire 66.5% and 33.5% of the shares of Liming Medical, respectively.
Answer all will create your authoritative image